EP300 and prostate cancer: Indeed, the combination of the p300/CBP catalytic inhibitor A‐485 and the BD inhibitor I‐CBP112 in a panel of prostate cancer cells has shown synergistic activity in inhibiting both p300 chromatin occupancy and cancer cell proliferation.[15]